ArticleFrontiers in microbiology2026
Evolutionary history and transmission dynamics of dengue virus type 2 in Africa.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Dengue virus serotype 2 (DENV-2) is a major driver of severe dengue outbreaks globally, yet its evolutionary history and transmission dynamics across Africa remain incompletely understood. Methods: To clarify its origins, introduction pathways, and patterns of regional spread, we compiled all available full-length DENV-2 genomes up to 16 July 2025, prioritizing African sequences while retaining representative global references. After quality filtering and down-sampling, a final dataset of 414 genomes was analyzed. Sequences were screened for recombination using RDP4 and analyzed with maximum-likelihood phylogenetics in IQ-TREE with 1,000 ultrafast bootstrap replicates. Temporal dynamics were inferred using time-scaled phylogenies reconstructed in BEAST under a strict molecular clock and exponential-growth coalescent prior, while viral dispersal was examined through discrete-trait phylogeographic analyses with Bayesian stochastic search variable selection. In parallel, single-nucleotide polymorphisms in the prM, E, and NS1 genes were characterized, and significant sites were mapped onto corresponding protein structures. Results and Discussion: Between 1964 and 2024, African DENV-2 diversity was shaped primarily by repeated introductions of the Cosmopolitan genotype, giving rise to geographically structured lineages. Lineage IIB, likely originating from La Réunion in the late 1970s, subsequently disseminated across West, Central, and East Africa, with Burkina Faso emerging as a key regional hub. Lineage IIA, also linked to La Réunion, diverged into two sub-lineages that expanded through East and Central Africa and extended into South Asia. In contrast, lineages IID and IIF were detected only sporadically, with limited geographic representation and no evidence of sustained regional expansion. Despite substantial genetic variation across prM, E, and NS1, relatively few significant non-synonymous mutations were identified, and critical N-glycosylation motifs remained conserved. This pattern suggests that epidemiological connectivity and repeated viral introductions, rather than sustained positive selection at major functional loci, are the dominant forces shaping DENV-2 spread in Africa. Overall, our findings highlight the central role of recurrent introductions and regional transmission networks in structuring DENV-2 circulation across the continent and emphasize the need for strengthened genomic surveillance to track lineage emergence and improve evidence-based dengue prevention and control strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.